Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology

Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

“…The selected variables reflected disease characteristics and treatment history, and were generally consistent with validated prognostic markers currently used in stratifying patients into different risk groups [23,24]. Details of the variable selection process have been reported previously [25,26]. Table 1 presents an overview of parameters used for the MAICs.…”